Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00454090 | AZD8330 First Time in Man in Patients With Advanced Malignancies | PHASE1 | COMPLETED | 83 | — | — | Mar 1, 2007 | Mar 1, 2011 | Aug 24, 2011 | 3 | United States, Norway |
| Name | Type | Description |
|---|---|---|
| AZD8330 | DRUG | oral tablet |
Inclusion Criteria: * Cancer which is refractory to standard therapies, or no therapies exist; Exclusion Criteria: * Participated in radiotherapy, biological or chemotherapy within 21 days prior to study start; * Hasn't participated in investigation drug study within 30 days; * Brain metastases/s...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |